Investing in Life Sciences Under the Trump Presidency

Contributed Opinion
Source: Kristin McFarland for The Life Sciences Report  (02/16/2017)
Investing in Life Sciences Under the Trump Presidency
Stocks in all areas of life sciences including biotech to pharma have been on a roller coaster since Donald Trump won the election in November. Wealth advisor Kristin McFarland discusses the big picture for pharmaceutical investment under the new administration. read more >

Regeneus Hits the Fast Track with Major Japanese Partnership

Source: The Life Sciences Report  (02/08/2017)
Regeneus Hits the Fast Track with Major Japanese Partnership
Regeneus, an Australian regenerative medicine company, has entered into a collaboration with a major Japanese firm to manufacture its stem cell therapy Progenza, a move that may accelerate approval and that has a pair of analysts optimistic about the company's future. read more >

Luminor Drives the Scout DS Forward

Contributed Opinion
Source: Bob Moriarty for The Life Sciences Report  (02/06/2017)
Luminor Drives the Scout DS Forward
Veteran investor Bob Moriarty discusses Luminor Medical Technologies, whose Scout DS technology offers a noninvasive diabetic screen, measuring blood-sugar levels without taking blood. read more >

The Future of Cannabis Investing

Contributed Opinion
Source: Tom Beck for Streetwise Reports  (02/03/2017)
The Future of Cannabis Investing
The cannabis industry attained new highs in 2016, paving the way for some big changes this year, says Tom Beck, senior editor of Portfolio Wealth Global. read more >

Companies Flocking to Japan for Biotech Deals

Source: Colin Lee Novick for The Life Sciences Report  (02/01/2017)
Companies Flocking to Japan for Biotech Deals
For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. Tokyo-based Colin Lee Novick, managing director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead. read more >

ContraVir's Hep B Drug Could Be a Game Changer

Source: The Life Sciences Report  (02/01/2017)
ContraVir's Hep B Drug Could Be a Game Changer
In light of a Q4/16 announcement by ContraVir Pharmaceuticals about the effectiveness of its compound targeting the hepatitis B virus (HBV), several analysts believe expanding its Phase 2a dose escalation trial could lead to positive results for a population that represents an unmet medical need, as well as for the company. read more >

Inovio's Zika Vaccine Generates Robust Immune Responses

Source: The Life Sciences Report  (01/25/2017)
Inovio's Zika Vaccine Generates Robust Immune Responses
Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers. read more >
Expert Investing Ideas

"SNSS has a potential blockbuster opportunity with SNS062."

–Jim Birchenough, Wells Fargo Securities


SCOTTSDALE CAPITAL CONFERENCE  in SCOTTSDALE, AZ
NASDAQ Biotech ARCA Pharmaceutical

2017 Small-Cap Biotech Watchlist: Takeaways for Investors

Source: The Life Sciences Report  (01/18/2017)
2017 Small-Cap Biotech Watchlist: Takeaways for Investors
Why should investors keep an eye on these twenty small-cap biotechs in 2017? The analysts who made the selections for The Life Sciences Report's 2017 Small-Cap Biotech Watchlist laid out their rationales at the Watchlist's launch at the Biotech Showcase in San Francisco on Jan. 11. read more >

Time to Go Long on BrainStorm Cell Therapeutics?

Contributed Opinion
Source: Jason Napodano CFA of BioNap Inc. for The Life Sciences Report  (01/16/2017)
Time to Go Long on BrainStorm Cell Therapeutics?
Jason Napodano of BioNap Consulting takes an in-depth look at BrainStorm Cell Therapeutics, including the science, the Phase 2 data and the potential valuation of the company developing adult stem cell-based therapies for neurodegenerative diseases. read more >

19 Companies Selected for the 2017 Small-Cap Biotech Watchlist

Source: The Life Sciences Report  (01/03/2017)
19 Companies Selected for the 2017 Small-Cap Biotech Watchlist
Now in its fifth year, the 2017 Life Sciences Report Biotech Watchlist includes nineteen small-cap biotech companies selected by top analysts in the field, and will be presented at the Biotech Showcase in San Francisco in January. read more >

Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries

Source: The Life Sciences Report  (12/21/2016)
Viveve's Technology for Women's Sexual Dysfunction Receives Regulatory Approval in 49 Countries
The last several months have been active ones for Viveve: The results of the VIVEVE I clinical trial were accepted for publication in the Journal of Sexual Medicine, third-quarter financial results beat expectations, and the Viveve system has received regulatory approvals in Brazil, U.A.E. and Lebanon and FDA 510(k) clearance in the U.S. read more >
Biotech Watchlist 2017